We describe here a molecular model of blastocyst implantation which is based on two assumptions: (i) that implantation of the human blastocyst into the endometrium is a process which is very similar to tumour invasion of a host tissue; and (ii) that the cytotrophoblastic cells of a first trimester pregnancy retain almost all the properties of the trophectodermal cells of the blastocyst and can thus be used as surrogates to study the implantation process in vitro. Our model considers that the trophectodermal cells, once they reach the endometrial basement membrane, express integrins (α6β4) which anchor them into the basement membrane and induce their secretion of gelatinases. These proteases digest the basement membrane, allowing the embryo to make contact with the endometrial extracellular matrix (ECM). Integrins (α5β1) anchor the embryo into the ECM and induce its secretion of collagenases. These enzymes digest the ECM, allowing the embryo to burrow into the endometrium. This process is under the paracrine control of endometrial cytokines and ECM glycoproteins.
Introduction
Implantation of the human blastocyst is a biological paradox that cannot be explained easily with our present level of knowledge of cell biology (Denker, 1993) . Indeed, it is still a mystery how two epithelial cells (the trophectodermal cells of the blastocyst and the endometrial epithelial lining) can make a contact through their apical membranes (apical membranes of epithelial cells are in general devoid of adhesion molecules). The situation becomes even more complicated when one realizes that implantation in the human is quite unique (Lindner, 1972; Bischof, 1991) and that the models developed from studies in other mammals are only vaguely applicable to the human. Even rhesus monkeys have a different implantation process (superficial implantation, limited decidualization, attachment at opposite poles, etc.). The uniqueness of human implantation is perhaps best illustrated by the fact that ectopic pregnancy is not an uncommon event in humans, whereas it is very rare in other species. It is obvious from the diversity of implantation patterns recognized among mammals (Wimsatt, 1975) that restricting the study of implantation to one species will not permit us to understand the events in humans. However, certain molecular mechanisms may be common to several species. Finn (1986) proposed that 'the response of a uterus to an implanting blastocyst bears considerable resemblance to inflammation and may have evolved from it'. This provocative statement, which considers that viviparity has used and modified the mechanisms of inflammation, points to the possibility that similar molecular mechanisms are involved in attachment and penetration.
Our study takes yet another approach to attempt to understand implantation in the human. Our approach is based on two assumptions which seem reasonable: (i) implantation of the human blastocyst into the endometrium is a process which is very similar to tumour invasion of a host tissue -implantation and metastatization thus share common biochemical intermediates (Wilson, 1963; Aplin, 1991; Denker, 1994) ; and (ii) the cytotrophoblastic cells of first trimester pregnancy retain almost all the properties of the trophectodermal cells of the blastocyst and thus can be used as surrogates to study the implantation process in vitro. Trophectodermal cells and villous cytotrophoblastic 1 To whom correspondence should be addressed at: Laboratoire d'Hormonologie Maternité, 1211 Geneva 14, Switzerland Step 1: transport. The blastocyst arrives in the uterus 132-144 h after fertilization (Findlay, 1984) .
Step 2: orientation. The inner cell mass is orientated towards the endometrial epithelial lining.
Step 3: hatching. The zona pellucida dissolves perhaps because of the secretion of proteases by trophectodermal cells.
Step 4: apposition. The blastocyst is now in close contact with the endometrial lining but no connections have been established. The embryo can still be dislodged by washing.
Step 5: adhesion. Connections of an unknown nature are established between the embryo and the endometrial epithelium. The embryo can no longer be dislodged. (b) Implantation of the human blastocyst step by step.
Step 6: invasion. Thin folds of trophectodermal cells intrude between the endometrial epithelial cells.
Step 7: syncytialization. Some trophectodermal cells fuse to form syncytia. These syncytia proliferate and invade the endometrial extracellular matrix.
Step 8: villous formation. The former trophectodermal cells, now called cytotrophoblastic cells, migrate between the syncytia followed by the fetal stroma. This will lead to the formation of the placental villi. cells are both stem cells which retain their capacity to form syncytia and both secrete metalloproteinases and human chorionic gonadotrophin (HCG; Fisher et al., 1985; Cross et al., 1994) . These assumptions allow us to present here a coherent but somewhat speculative molecular model of how implantation of the blastocyst might occur in the human species.
Implantation step by step
Orchestrating the blastocyst-endometrial summit requires a perfect synchronization between embryo development and endometrial maturation. This synchronization involves not only the embryo and the endometrium but also maternal pituitary and the ovary. Because of ovarian oestradiol and progesterone secretion, the endometrium proliferates and differentiates. During the mid-luteal phase (days 22-24 of the cycle), decidualization starts around the spiral arteries and extends to the whole endometrium within a few days. The endometrial extracellular matrix (ECM) becomes distended as water is attracted, possibly because of the decidual secretion of hygroscopic molecules such as heparan sulphate proteoglycans. This is the milieu in which the blastocyst will implant (Figure 1a and b) .
Once the blastocyst reaches the uterine cavity (5-6 days after ovulation), it orientates its embryonic pole towards the uterine epithelium and hatches. Hatching exposes the very invasive trophectodermal cells which can now appose, attach and invade the epithelial lining ( Figure 1a) .
In humans, implantation is intrusive (invasion proceeds between epithelial cells without destroying them), interstitial (the embryo implants deeply) and antimesometrial because it occurs most of the time in the upper part of the posterior wall of the uterus near the mid-sagittal plane (Boyd and Hamilton, 1970) . Intrusive invasion (characteristic of highly invasive trophoblast) starts with the formation of thin folds of trophectodermal cells (invadopodia) which progress between the adjacent endometrial epithelial cells to reach the underlying basement membrane. This membrane is destroyed, allowing the trophectodermal cells to reach the stromal compartment. Some trophectodermal cells fuse to form a syncytium (Figure 1b) , which proliferates and invades the endometrium. At 8 days after ovulation the blastocyst is completely embedded in the uterine stroma and the site of entry is covered by fibrin, over which the uterine epithelial cells grow. In the syncytiotrophoblast (STB), fluid-filled spaces separated by trabeculae appear, trans- forming the STB into a sponge-like material. The trabeculae are arranged radially, and cytotrophoblastic cells (CTB; the former unfused trophectodermal cells) proliferate within the trabeculae, leading to the formation of primary chorionic villi. With time, the primary villi grow and branch into secondary and tertiary villi, a process known as placentation.
By looking at a section of an implantation site at 10-12 weeks of pregnancy one can clearly distinguish two types of placental villi (Figure 2 ): the floating and the anchoring villi. They both have the same structures, with an outer layer of STB covering a monolayer of CTB. The epithelial cells are separated from the underlying fetal stroma by a basement membrane. While the floating villi can move freely in the intervillous space, the anchoring villi make contact with the decidualized endometrium.
At the tip of these last villi the STB disappears (apoptosis?), allowing the underlying CTB to proliferate and to invade the entire decidua, including the spiral arteries and the proximal third of the myometrium. These CTB can fuse and form syncytia (giant cells) at distant sites. The anchoring villous is thus formed by two populations of CTB: the villous and extravillous (or intermediate) CTB (Yeh and Kurman, 1990) . These cells are phenotypically very different: villous CTB are immotile, polarized epithelial stem cells which terminally differentiate into syncytia; extravillous CTB have transiently differentiated into motile and invasive unpolarized epithelial cells and resemble mesothelial cells but have no vimentin filaments in their cytoskeleton.
The biochemistry of implantation
As described above, implantation and placentation are physiological mechanisms which rely upon one fundamental biological process: trophoblastic invasion. Trophoblastic invasion is of paramount importance for the survival of our species. Trophoblastic invasion of the endometrial spiral arteries changes their properties (reduced muscular and elastic strength), thus allowing an adequate blood supply to the rapidly growing fetoplacental unit (Blankenship et al., 1993) . Insufficient endovascular invasion is associated with hypertension, pre-eclampsia and inadequate fetal growth, whereas unrestricted trophoblastic invasion leads to a variety of pre-malignant conditions such as placenta accreta, hydatidiform moles and choriocarcinoma.
Our basic understanding of invasion comes from studies performed with tumour cells and not with trophoblastic cells. We postulate here that both types of cell share the same biochemical intermediates to ensure invasion. Invasion is not caused by passive growth but by an active biochemical process. The acquisition of an invasive phenotype is independent of the genetic changes that result in uncontrolled cellular proliferation associated with tumorigenesis. The acquisition of metastatic properties requires additional genetic changes (possibly the activation of oncogenes) beyond those related to tumour growth (Aznavoorian et al., 1993) . The transition from a proliferating tumour cell to a metastatic cell is defined by the ability of the tumour cell to detach from the bulk of the primary tumour, to invade the surrounding tissues and to cross the basement membranes. Crossing the basement membranes and invading the ECM requires an active proteolysis of their constituents, such as the different types of collagen (types I-X), matrix glycoproteins (laminin, fibronectin, elastin, entactin, etc.) and proteoglycans. Thus a cell is considered to be invasive by virtue of its ability to secrete proteases (Mullins and Röhrlich, 1983) . Some molecular aspects of implantation have been reviewed recently (Tabibzadeh and Babaknia, 1995) .
CTB secrete an array of proteolytic enzymes, and among these are matrix metalloproteinases (MMP), the only enzymes capable of digesting the endometrial ECM (Fisher et al., 1985 (Fisher et al., , 1989 Moll and Lane, 1990; Bischof et al., 1991; Bischof and Martelli, 1992) . Increased MMP expression has clearly been shown to correlate with the invasiveness of several tumour types (Goldberg and Eisen, 1990) .
MMP form a family of homologous enzymes which all have a Zn 2+ atom in their active site (for a review see Matrisian, 1990) . They are secreted as inactive proenzymes (zymogens), which become activated upon partial hydrolysis whereby they lose their propeptide. They are classified into three subfamilies according to their substrate specificity (Figure 3 ). Gelatinases are represented by two enzymes, gelatinase A and B (72 and 92 kDa gelatinases or MMP-2 and MMP-9 respectively). These proteases digest collagen type IV (the major constituent of basement membranes) and denatured collagen (gelatine). Collagenases include three proteases: the interstitial collagenase (MMP-1 or collagenase), the neutrophil collagenase (MMP-8) and collagenase 3 (MMP-13). These enzymes digest collagen types I-III, VII and X. They are thus appropriate for digesting the collagens of the ECM of the interstitium. Stromelysins are a subfamily of four As an example of how TIMP act, the binding of TIMP to MMP-2 is presented (adapted from Willenbrock et al., 1993) . The N-terminal domain of MMP-2 is to the left and the C-terminus to the right of the molecule. TIMP-2 binds to MMP-2 and to proMMP-2 (note the presence of the propeptide) by electrostatic interactions with the C-terminal domain and by interactions with the catalytic domain. TIMP-1 binds MMP-2 in the catalytic domain only. Note that the complexed form is preferred to the free form of the enzyme.
enzymes: MMP-3, MMP-7, MMP-10 and MMP-11 (also called stromelysin-1, matrilysin, stromelysin-2 and stromelysin-3 respectively). These proteases have a relatively broad substrate specificity and digest collagen types IV, V and VII, as well as laminin, fibronectin, proteoglycans and gelatine. Activation of the proMMP into active MMP can be reproduced in vitro by the addition of different agents such as mercurial salts. Although the physiological activators of the different MMP are unknown, it has been shown that plasmin (Murphy et al., 1992) and MMP-3 (Ogata et al., 1992) are potent activators of several MMP. This suggests that MMP most probably act in a cascade like the enzymes involved in blood coagulation (Figure 4) . Activated enzymes digest the ECM without damaging the cells. For all except one MMP (MMP-2) it is considered that the active enzymes are secreted into the extracellular space where they digest the matrix components and are under the control of local inhibitors. So far, three tissue inhibitors of MMP (TIMP-1, TIMP-2 and TIMP-3) have been described. These are homologous, cysteine-rich proteins secreted locally in the extracellular space where they control the activity of MMP ( Figure 5 ). TIMP inhibit tumour cell invasion in vitro and in vivo (Goldberg and Eisen, 1990 ) by binding to the MMP.
For MMP-2, however, Emonard et al. (1992) reported the existence of an MMP-2 binding site on human breast cancer cells. Recently, Sato et al. (1994) described a membrane-bound MMP, called MT-MMP, which is capable of binding and activating proMMP-2. These and other observations led Murphy and her group (Cockett et al., 1994) to propose a model for MMP-2-dependent tumour cell invasion (Figure 6 ). According to their model, proMMP-2 is bound via its C-terminus to the cell surface through a binding site located at the invading front of a tumour. This exposes the fibronectin-like collagen binding domain which interacts with the surrounding collagen. Upon activation, possibly through a cell membrane-associated mechanism, MMP-2 degrades collagen and facilitates invasion. TIMP-2, by binding to the C-terminus of the proMMP-2, can inhibit activation possibly by competing with the binding of proMMP-2 to the cell surface binding site.
As described above, CTB secrete MMP and particularly MMP-2 and MMP-9 . CTB are thus capable of digesting the collagen type IV of the endometrial basement membrane after activation of their proMMP. The physiological activator (plasmin or MMP-3) and the type of activation (cell-bound or not) are unknown so far. The property of trophoblastic cells to produce and secrete MMP is acquired very early in development because it has been shown that human blastocysts produce collagen type IV-degrading enzymes (Puistola et al., 1989) . MMP-9 seems to be constitutively expressed in trophoblastic cells because purified (97% pure) CTB from first trimester pregnancies express MMP-9 mRNA (P.Bischof, unpublished observation). These MMP are responsible for trophoblast invasion, as illustrated by the fact that the in-vitro trophoblastic invasion of Matrigel (a reconstituted basement membrane) is inhibited by o-phenanthroline, a well-known inhibitor of MMP (Bischof et al., 1995b) . All MMP are not equally important for trophoblastic invasion. In the case of the invasion of Matrigel, only function-perturbing antibodies to MMP-9 (and not to MMP-1, MMP-2 and MMP-3) inhibit invasion (Librach et al., 1991; Bischof et al., 1995b) . This would not have been the case if, instead of Matrigel, collagen type I had been chosen (MMP-9 cannot digest collagen type I, but MMP-1 is able to do so). In other words, CTB and tumour cells have the capacity to recognize and adapt to their immediate environments by secreting and activating an MMP with the appropriate substrate specificity to digest the matrix on which they are resting (Emonard et al., 1990) . For more details about the nature of the endometrial matrices, the reader is referred to the excellent study by Damsky et al. (1992) . This recognition of the immediate cell environment occurs through cell adhesion molecules (CAM) located on the plasma membrane.
CAM are represented by three subfamilies of molecules: cadherins, immunoglobulins and integrins. Cadherins are membrane glycoproteins involved in Ca-dependent cell-cell binding, immunoglobulins allow cell-cell binding in a Ca-independent manner and integrins mainly Integrins during trophoblast invasion. Villous cytotrophoblastic cells (CTB) resting on the basement membrane express the integrin α6β4 (a laminin receptor) clustered towards the basement membrane. While leaving the villous and forming cell columns, CTB still express the integrin α6β4 but in an unclustered manner. CTB located deeper in the placental bed have lost their capacity to express the integrin α6β4 and instead express the integrin α5β1, a fibronectin receptor. CTB that invaded the uterine blood vessels express the collagen receptor α1β1. For a description of the four zones see the legend to Figure 2. (but not exclusively) regulate Ca-dependent cell-substrate interactions. Integrins are widely expressed cell surface adhesion receptors. They are all αβ heterodimers ( Figure  7 ). So far eight β and 14 α subunits have been cloned and sequenced, but several alternatively spliced forms have also been described (for a review see Hynes, 1992) . Depending on the type of αβ combination, the integrin will bind to one or another matrix glycoprotein, i.e. α5β1 will bind to fibronectin, α2β1 will bind to laminin, etc. Both integrin subunits are transmembrane glycoproteins with a short cytoplasmic domain, a single transmembrane segment and a large extracellular domain (Figure 7) .
Integrins are considered to be transducers signalling the nature of the extracellular environment to the interior of the cell. This signal is then translated into events which allow the cell to change shape, migrate, adhere to other matrices and release proteases. This will, in turn, modify the micro-environment of the cell, to which it will re-adapt by changing its integrin repertoire. Precisely how the transduction mechanism works is unclear as yet, but it involves the clustering of integrins at focal contacts on the cell membrane, the phosphorylation of the kinase focal adhesion kinase 125 and possibly the induction of gene transcription (Kornberg and Juliano, 1992; Figure 8) . Integrins are causally related to invasion, as demonstrated by the transfection of Chinese hamster ovary cells with cDNA for the integrin α5β1 (Giancotti and Ruoslahti, 1990) . The increased expression of α5β1 (a fibronectin receptor) on these cells inhibited their capacity to form tumours and to migrate. This suggests that enhancing the adhesion of a cell reduces its invasive potential.
CTB also express integrins. Immunohistochemical (Korhonen et al., 1991; Damsky et al., 1992; Aplin, 1993; Bischof et al., 1993) and functional studies (Burrows et al., 1995) have highlighted a fascinating property of CTB: they modulate their integrin repertoire during invasion of the endometrium. Villous CTB are immotile stem cells resting on the villous basement membrane (Figure 9 , zone 1). They express the integrin α6β4 (a laminin receptor) in a clustered manner towards the basement membrane. When these cells leave the villous tree to form CTB cell columns ( Figure 9 , zones 2 and 3) they continue to express the integrin α6β4 but in an unclustered way. Thus, the delocalization of α6β4 allows the CTB to become motile and to start the invasion of the endometrium. CTB located deeper in the decidualized endometrium ( Figure 9 , zone 4) have lost their capacity to express the integrin α6β4 and instead express the integrin α5β1, the major fibronectin receptor. CTB which have invaded the endometrial blood vessels express yet another integrin, α1β1, a known collagen receptor. These observations show that CTB adapt to their successive environments: the placental basement membrane, the cell columns, the placental bed and the endometrial blood vessels. This adaptation changes not only the integrin repertoire of the CTB but also their metabolism.
Recently we observed (Bischof et al., 1995a,b) that CTB isolated from first trimester trophoblast and expressing the α6 integrin subunit secreted significantly higher concentrations of gelatinases and significantly lower concentrations of fibronectin than the CTB expressing the α5 integrin subunit. In contrast, both CTB subsets secreted similar amounts of HCG. We conclude from these studies that during trophoblast invasion, extravillous CTB expressing the α6β4 integrin (in an unclustered way) represent the invasive population of CTB. Once the cells express the α5β1 integrin, their invasive behaviour and their gelatinase (MMP-9) secretion has almost stopped and the cells become immotile and secrete fibronectin. This fibronectin secretion is deposited in the ECM and contributes towards anchoring the CTB to the endometrium.
Glycoproteins of the ECM, such as laminin and fibronectin, are certainly not the only regulators of trophoblast invasion. It is quite clear that there are other endometrial regulatory factors. For example, transforming growth factor-β1 (TGF-β1) is a cytokine produced by macrophages, fibroblasts and T cells and has been immunolocalized in decidual fibroblasts, glandular endometrial cells and extravillous CTB (Graham et al., 1992) . This cytokine exerts potent inhibitory effects on CTB invasiveness by stimulating the secretion of decidual TIMP, which in turn inhibits the activity of MMP secreted by the invading CTB (Graham et al., 1992) . Epidermal growth factor (EGF) is another cytokine secreted by many cells, including decidual cells (Haining et al., 1991) but not CTB (Bass et al., 1994) . However, villous CTB express the 170 kDa EGF receptor. Bass et al. (1994) elegantly showed that EGF produced a several-fold increase in the invasive capacity of first trimester CTB. Endometrial EGF and TGF-β1 thus have opposite effects and can by themselves explain the endometrial modulation of trophoblast invasion. This does not mean that the endometrial regulation of CTB invasion is limited to these two cytokines -the in-vivo situation might be much more complicated. Nevertheless, these observations clearly demonstrate that the decidualized endometrium controls, in a paracrine or juxtacrine manner, the degree of trophoblast invasion during implantation and placentation.
The observations and the results of in-vitro studies described so far lead us to propose the biochemical model of blastocyst implantation described in Figure 10 . This somewhat speculative model is intended to be a guide for formulating hypotheses about the mechanisms allowing implantation rather than a schematic representation of how implantation really occurs. For a detailed description of our model the reader is referred to the legend to Figure 10 .
